Viable Research Management LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$12,750	1
2023	Research	$79,433	1
2022	Research	$6,407	1
2021	Research	$110,480	1
2020	Research	$196,766	3
2019	Research	$208,079	4

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca Pharmaceuticals LP $341,613 6 payments
AstraZeneca UK Limited $261,303 4 payments
Kadmon Corporation LLC $11,000 1 payment

Studies the money was for Research payments · program years 2019–2025

A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia $393,845 6 payments
A Phase 2a Randomized Double blind Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease $196,320 3 payments
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event $12,750 1 payment
A Phase 2, Randomized, Placebo controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis $11,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.